.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Pediatric Cancer
Federal Research Institute of Pediatric Hematology, Oncology and ImmunologySmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
33 Active assets in the Pediatric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
(+)-VINCRISTINE Tianjin Medical University Cancer Institute and Hospital | Phase 2 | BB |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 2 | BB |
Nivolumab Australian & New Zealand Children's Haematology/Oncology Group | Phase 2 | B |
Ifosfamide Samsung Medical Center | Phase 2 | B |
OTL-38 Mayo Clinic | Phase 3 | B |
View all 50 →
Same molecule, other indications
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →